MEI Pharma, Inc. (MEIP): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a pharmaceutical company navigates the complex world of cancer therapy development? MEI Pharma, Inc. (MEIP), a clinical-stage company, focuses on creating novel treatments to improve patient outcomes. But how exactly does it operate and generate revenue? Keep reading to discover the history, ownership structure, mission, and financial strategies that drive MEI Pharma.

MEI Pharma, Inc. (MEIP) History

MEI Pharma, Inc.'s Founding Timeline

Year established

MEI Pharma, Inc. was established in 2000.

Original location

The company is headquartered in San Diego, California.

Founding team members

Details about the specific founding team members are not readily available in the provided search results.

Initial capital/funding

Information regarding the initial capital or funding of MEI Pharma during its establishment is not available in the provided search results.

MEI Pharma, Inc.'s Evolution Milestones

MEI Pharma, Inc.'s Transformative Moments

• Strategic Partnerships and Licensing Agreements: MEI Pharma's ability to forge key partnerships with companies like Helsinn Group, Daiichi Sankyo, and Kyowa Kirin significantly de-risked its drug development programs and provided substantial financial resources. These collaborations validated the potential of its drug candidates and expanded its global reach.
• FDA Approval of Zandelisib: The FDA's accelerated approval of zandelisib in 2023 was a pivotal moment, marking MEI Pharma's transition from a development-stage company to a commercial entity. This approval not only provided a treatment option for patients with relapsed or refractory follicular lymphoma but also opened up new revenue streams for the company.
• Acquisition by Infinity Pharmaceuticals: The acquisition of MEI Pharma by Infinity Pharmaceuticals in 2024, leading to the formation of VerImmune, represented a strategic shift towards a new focus and direction. This merger aimed to combine the strengths of both companies to create a more robust entity with a broader portfolio and pipeline.

For more information, you might find this link helpful: Mission Statement, Vision, & Core Values of MEI Pharma, Inc. (MEIP).

MEI Pharma, Inc. (MEIP) Ownership Structure

Understanding the ownership structure of MEI Pharma, Inc. provides valuable insights into the company's control and governance. A diverse range of shareholders, from institutional investors to individual stakeholders, influences the company's strategic direction.

MEI Pharma, Inc.'s Current Status

MEI Pharma, Inc. is a publicly traded company, meaning its shares are available for purchase on the open market. This allows a wide array of investors to own a portion of the company and participate in its financial performance. Being publicly traded entails certain regulatory requirements and reporting obligations, ensuring transparency and accountability to shareholders.

MEI Pharma, Inc.'s Ownership Breakdown

The ownership of MEI Pharma, Inc. is distributed among various types of shareholders. Institutional investors, mutual funds, and individual investors all hold stakes in the company. The following table summarizes the ownership breakdown:

MEI Pharma, Inc.'s Leadership

The leadership team is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:

• David M. Urso: President and Chief Executive Officer
• Brian Drazba: Chief Financial Officer
• Dr. Kristina Herbert: Chief Medical Officer

These individuals, along with other members of the executive team, bring a wealth of experience and expertise to MEI Pharma, Inc., guiding the company towards its strategic goals. You might also be interested in: Mission Statement, Vision, & Core Values of MEI Pharma, Inc. (MEIP).

MEI Pharma, Inc. (MEIP) Mission and Values

MEI Pharma, Inc. is dedicated to developing and commercializing novel cancer therapies, striving to improve patient outcomes through targeted approaches. Their mission is reflected in their commitment to scientific innovation and addressing unmet medical needs in oncology.

MEI Pharma's Core Purpose

Official mission statement

MEI Pharma's mission statement, as detailed on their website, is: 'To build a portfolio of novel drug candidates with the potential to address unmet medical needs in cancer and other serious diseases.' This statement underscores their focus on:

• Innovation: Developing new drug candidates.
• Impact: Addressing unmet medical needs.
• Focus: Concentrating on cancer and other serious diseases.

Vision statement

While a specific formal vision statement is not explicitly provided, MEI Pharma's vision can be inferred from their actions and goals:

• Leading in Oncology: Becoming a recognized leader in providing innovative cancer therapies.
• Improving Patient Lives: Significantly enhancing the quality of life and treatment outcomes for patients.
• Sustainable Growth: Building a sustainable and successful biopharmaceutical company.

Company slogan/tagline

MEI Pharma does not have a widely publicized official slogan or tagline. However, their corporate communications and activities suggest an implied tagline centered around:

• Innovation for Life: Reflecting their dedication to creating innovative solutions that improve and extend life.
• Targeting Cancer, Transforming Lives: Highlighting their focus on targeted cancer therapies and their transformative impact on patients.

For more in-depth information, you can explore: Mission Statement, Vision, & Core Values of MEI Pharma, Inc. (MEIP).

MEI Pharma, Inc. (MEIP) How It Works

MEI Pharma, Inc. is a pharmaceutical company focused on the development and commercialization of novel cancer therapies. They aim to create value by developing and bringing to market treatments that address unmet medical needs in oncology.

MEI Pharma's Product/Service Portfolio

MEI Pharma's Operational Framework

MEI Pharma operates through a framework centered on:

• Drug Development: Identifying and developing promising drug candidates, focusing on oncology. This includes preclinical research, clinical trials, and regulatory submissions.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates. These trials are essential for obtaining regulatory approval.
• Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to expand their pipeline and accelerate drug development. For instance, MEI Pharma has a licensing agreement with GC Pharma for Voruciclib.
• Regulatory Approval: Seeking regulatory approval from agencies like the FDA to commercialize their drugs.
• Commercialization: Bringing approved drugs to market, which may involve direct sales, marketing, and distribution, or partnering with other companies for commercialization.

MEI Pharma's Strategic Advantages

MEI Pharma's strategic advantages include:

• Focused Pipeline: A focused pipeline of oncology drug candidates targeting specific unmet needs.
• Novel Mechanisms of Action: Developing drugs with novel mechanisms of action, which may provide advantages over existing therapies.
• Strategic Partnerships: Forming strategic partnerships to leverage resources and expertise.
• Experienced Management Team: An experienced management team with a track record of drug development and commercialization.

To gain more insights into the values that guide their work, explore: Mission Statement, Vision, & Core Values of MEI Pharma, Inc. (MEIP).

MEI Pharma, Inc. (MEIP) How It Makes Money

MEI Pharma, Inc. is a pharmaceutical company that primarily focuses on the clinical development of novel therapies for cancer. Revenue is generated through strategic collaborations and licensing agreements with other pharmaceutical companies, as well as from government grants and contracts.

MEI Pharma, Inc.'s Revenue Breakdown

MEI Pharma, Inc.'s Business Economics

• MEI Pharma, Inc. operates in the biotechnology sector, which is characterized by high research and development costs and a lengthy drug development process.
• The company's profitability is heavily influenced by its ability to successfully develop and commercialize its drug candidates, as well as secure and maintain partnerships.
• Pricing strategies for pharmaceutical products are complex and affected by factors such as clinical trial data, market competition, and regulatory approvals.
• Economic fundamentals for MEI Pharma, Inc. are tied to the overall health of the biotechnology industry, investor sentiment towards biotech companies, and healthcare policies regarding drug pricing and reimbursement.

MEI Pharma, Inc.'s Financial Performance

• Revenue Recognition: Revenues are recognized based on the terms of collaboration agreements, typically involving upfront payments, milestone payments, and royalties on future sales.
• R&D Expenses: A significant portion of the company's expenditure is allocated to research and development, reflecting its focus on advancing its pipeline of drug candidates.
• Operating Expenses: Includes general and administrative costs required to manage the company, comply with regulations, and support business operations.
• Net Loss: As a clinical-stage biopharmaceutical company, MEI Pharma, Inc. often reports a net loss due to substantial R&D investments and the absence of consistent product revenue until a drug is commercialized.

To gain more in-depth insights into the financial health of MEI Pharma, Inc., refer to this analysis: Breaking Down MEI Pharma, Inc. (MEIP) Financial Health: Key Insights for Investors

MEI Pharma, Inc. (MEIP) Market Position & Future Outlook

As of April 2025, MEI Pharma, Inc. faces a dynamic market landscape, balancing promising opportunities with inherent challenges in the pharmaceutical sector. The company's future hinges on its ability to navigate these complexities while leveraging its strategic initiatives.

Competitive Landscape

Opportunities & Challenges

Industry Position

MEI Pharma operates within the highly competitive pharmaceutical industry, specifically focusing on oncology. Its standing is characterized by:

• Niche player with a specialized pipeline.
• Emphasis on developing novel therapies for cancer treatment.
• Seeking strategic collaborations to enhance its market presence.

To gain a deeper understanding of the investors and motivations behind MEI Pharma, explore: Exploring MEI Pharma, Inc. (MEIP) Investor Profile: Who’s Buying and Why?